Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O™ to Treat Opioid Use Disorder

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for reSET-O™.